Johnson Pharmacare Share Price
0.47+0.00 (+0.00%)
-41.25% past 1 Year
Johnson Pharmacare is in the business of wholesale and retail trade of all kinds of pharmaceuticals, antibiotics, drugs, medicines, biological, neutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines,
Corporate filings & documents
Announcements
Pursuant to regulation 47 of LODR 2015 -Submission of extract of Newspaper Publication for the unaudited financial result for the quarter ended 30th June 2026.
3 weeks agoPursuant to regulation 47 of LODR 2015 -Submission of extract of Newspaper Publication for the unaudited financial result for the quarter ended 30th June 2026.
3 weeks agoUndertaking for non - applicability of reg 32 of sebi (lodr) reg 2015
3 weeks agoUndertaking for non - applicability of reg 32 of sebi (lodr) reg 2015
3 weeks agoSubmission of Un-Audited Financial Results for the Quarter ended on June 30th 2026 and along with Limited Review Report Thereon.
3 weeks agoSubmission of Un-Audited Financial Results for the Quarter ended on June 30th 2026 and along with Limited Review Report Thereon.
3 weeks agoUN-AUDITED FINANCIAL RESULTSThe Board of Director have considered and approved the Un-Audited Financial Results along with Limited Review Report thereon for quarter ended on June 30th 2026. In this regard please find enclosed herewith the Un-Audited Financial Results along with Limited Review Report for the quarter ended on June 30th 2026 pursuant to the Regulation 33 of SEBI (LODR) Regulations 2015. The copy of the said Un-Audited quarterly financial results along with Limited Review Report by Statutory auditor of the company is enclosed herewith.STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LODR) REGULATIONS 2015
3 weeks agoUN-AUDITED FINANCIAL RESULTSThe Board of Director have considered and approved the Un-Audited Financial Results along with Limited Review Report thereon for quarter ended on June 30th 2026. In this regard please find enclosed herewith the Un-Audited Financial Results along with Limited Review Report for the quarter ended on June 30th 2026 pursuant to the Regulation 33 of SEBI (LODR) Regulations 2015. The copy of the said Un-Audited quarterly financial results along with Limited Review Report by Statutory auditor of the company is enclosed herewith.STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LODR) REGULATIONS 2015
3 weeks agoThe Exchange and Investors are hereby informed that boards of directors of the company had accorded thier approval for shifting of Registered Office of the Company from Existing Address to I-460 Titanium City Centre Mall Near Sachin Tower Anand Nagar Road Satellite Ahemdabad Gujrat 380009
3 weeks agoThe Exchange and Investors are hereby informed that boards of directors of the company had accorded thier approval for shifting of Registered Office of the Company from Existing Address to I-460 Titanium City Centre Mall Near Sachin Tower Anand Nagar Road Satellite Ahemdabad Gujrat 380009
3 weeks agoJohnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve To consider and approve the Un-Audited (Standalone) Financial Results of the Company for the Quarter ended on 30th June 2026.This is also to inform that the Trading Window of the Company has been closed from 01st July 2026 and will remain closed till the completion of 48 hours after the declaration of unaudited (Standalone) Financial Results of the Company for the quarter ended on 30th June 2026.2. Any other agenda with prior permission of Chairperson.
3 weeks agoJohnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve To consider and approve the Un-Audited (Standalone) Financial Results of the Company for the Quarter ended on 30th June 2026.This is also to inform that the Trading Window of the Company has been closed from 01st July 2026 and will remain closed till the completion of 48 hours after the declaration of unaudited (Standalone) Financial Results of the Company for the quarter ended on 30th June 2026.2. Any other agenda with prior permission of Chairperson.
3 weeks agoSubmission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended on 30th June 2026.
1 month agoSubmission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended on 30th June 2026.
1 month agoIntimation of Closure of Trading Window
2 months agoIntimation of Closure of Trading Window
2 months agoSubmission of Audited Financial Results of Jhonson Pharmacare ltd for the quarter and year ended on March 31st March 2026
2 months agoSubmission of Audited Financial Results of Jhonson Pharmacare ltd for the quarter and year ended on March 31st March 2026
2 months agoPursuant to Regulation 30 of SEBI (LODR) Regulations 2015 there is change.
2 months agoPursuant to Regulation 30 of SEBI (LODR) Regulations 2015 there is change.
2 months agomeeting of board of director to considered and approved the following 1.audited financial results 2. Statement of deviation or variation 3. take note on resignation of Rajendra prasad (Non- executive director) 4. take note on resignation of umesh kumar (executive director)
3 months agomeeting of board of director to considered and approved the following 1.audited financial results 2. Statement of deviation or variation 3. take note on resignation of Rajendra prasad (Non- executive director) 4. take note on resignation of umesh kumar (executive director)
3 months agoAnnual secretarial compliance report for the F.Y 31ST MARCH 2026
3 months agoAnnual secretarial compliance report for the F.Y 31ST MARCH 2026
3 months agoSubmission of Extract of Newspaper Publication of Audited (Standalone) Financial Results for the quarter and year ended on 31st March 2026
3 months agoDIsclosure of RPT
3 months agoDIsclosure of RPT
3 months agoUndertaking for Non- Applicability of Regul;ation 32 of SEBI (LODR) Regulation 2015 for the quarter and financial year ended 31st March 2026
3 months agoUndertaking for Non- Applicability of Regul;ation 32 of SEBI (LODR) Regulation 2015 for the quarter and financial year ended 31st March 2026
3 months agoSubmission of audited financial results for the quarter and financial year ended 3st March 2026
3 months agoSubmission of audited financial results for the quarter and financial year ended 3st March 2026
3 months agoSubmission of audited financial results for the quarter and financial year ended 3st March 2026
3 months agoSubmission of audited financial results for the quarter and financial year ended 3st March 2026
3 months agoPursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015 we wish to inform that the meeting of the Board of Directors of the Company was held today i.e. Wednesday 27th May 2026 which commenced at 07:15 P.M. and concluded at 07:45 P.M. at the registered office of the companyat Office No. 4-D Fourth Floor Vardan Tower Lakhudi Circle Near Sardar Patel Stadium Navrangpura Ahmedabad City Gujarat India 380009 have considered and approved the following:
3 months agoPursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015 we wish to inform that the meeting of the Board of Directors of the Company was held today i.e. Wednesday 27th May 2026 which commenced at 07:15 P.M. and concluded at 07:45 P.M. at the registered office of the companyat Office No. 4-D Fourth Floor Vardan Tower Lakhudi Circle Near Sardar Patel Stadium Navrangpura Ahmedabad City Gujarat India 380009 have considered and approved the following:
3 months agoJohnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve To consider and approve the Audited Financial Results of the Company for the Quarter & year ended on 31st March 2026.This is also to inform that the Trading Window of the Company has been closed from 01st April 2026 and will remain closed till the completion of 48 hours after the declaration of audited Financial Results of the Company for the quarter & year ended on 31st March 2026.2. Any other agenda with prior permission of Chairperson.
3 months agoJohnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve To consider and approve the Audited Financial Results of the Company for the Quarter & year ended on 31st March 2026.This is also to inform that the Trading Window of the Company has been closed from 01st April 2026 and will remain closed till the completion of 48 hours after the declaration of audited Financial Results of the Company for the quarter & year ended on 31st March 2026.2. Any other agenda with prior permission of Chairperson.
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Johnson Pharmacare Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L51100GJ1994PLC022388</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>NEHA SRIVASTVA</td></tr><tr><td>Designation :-</td><td>Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Dheeraj kumar</td></tr> <tr><td>Designation : -</td><td>Director</td></tr></table><div> <br/> Date: 09/05/2026<br/><br/></div>
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Johnson Pharmacare Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L51100GJ1994PLC022388</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>NEHA SRIVASTVA</td></tr><tr><td>Designation :-</td><td>Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Dheeraj kumar</td></tr> <tr><td>Designation : -</td><td>Director</td></tr></table><div> <br/> Date: 09/05/2026<br/><br/></div>
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Johnson Pharmacare Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L51100GJ1994PLC022388</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NEHA SHRIVASTAVA <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Umesh Kumar <br/> Designation: Director <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Johnson Pharmacare Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L51100GJ1994PLC022388</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NEHA SHRIVASTAVA <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Umesh Kumar <br/> Designation: Director <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoDisclosure as per Regulation 30 of SEBI (LODR) Regulation 2015
4 months agoDisclosure as per Regulation 30 of SEBI (LODR) Regulation 2015
4 months agoDisclosure as per Regulation 30 of SEBI (LODR) Regulation 2015Appointment of MR. Nand Kishore Ray as Additional Non -Executive &Non- Independent Director and Appointment of mr. Dheeraj Kumar as Additional Executive Director.
4 months agoDisclosure as per Regulation 30 of SEBI (LODR) Regulation 2015Appointment of MR. Nand Kishore Ray as Additional Non -Executive &Non- Independent Director and Appointment of mr. Dheeraj Kumar as Additional Executive Director.
4 months ago1. The Board has appointed Mr. Nand Kishore Ray (DIN: 11626638) as an Additional(Non-Executive & Non-Independent Director) of the Company w.e.f 17th April 2026 The Board has appointed Mr. Dheeraj Kumar (DIN: 11666616) as an Additional(Executive Director) of the Company w.e.f 17th April 2026 a brief profile pursuant to SEBICircular dated CIR/CFD/CMD/4/2015 dated September 09 2015 is enclosed as (Attachedherewith as Annexure)The Board has considered and approved resignation of Mr. Rajender Parsad (DIN:10871533) as an Additional & Non-Executive Director of the Company w.e.f 17th April 2026 The Board has considered and approved resignation of Mr. Umesh Kumar (DIN:07015921) as an Additional & Executive Director of the Company w.e.f 17th April 2026
4 months ago1. The Board has appointed Mr. Nand Kishore Ray (DIN: 11626638) as an Additional(Non-Executive & Non-Independent Director) of the Company w.e.f 17th April 2026 The Board has appointed Mr. Dheeraj Kumar (DIN: 11666616) as an Additional(Executive Director) of the Company w.e.f 17th April 2026 a brief profile pursuant to SEBICircular dated CIR/CFD/CMD/4/2015 dated September 09 2015 is enclosed as (Attachedherewith as Annexure)The Board has considered and approved resignation of Mr. Rajender Parsad (DIN:10871533) as an Additional & Non-Executive Director of the Company w.e.f 17th April 2026 The Board has considered and approved resignation of Mr. Umesh Kumar (DIN:07015921) as an Additional & Executive Director of the Company w.e.f 17th April 2026
4 months agoCertificate under Regulation 74(5) of SEBI ( Depositories and Participants) Regulations 2018 for the quarter and year ended 31st March 2026
4 months agoCertificate under Regulation 74(5) of SEBI ( Depositories and Participants) Regulations 2018 for the quarter and year ended 31st March 2026
4 months agoIntimation of Closure of Trading Window as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation 2015 for the Quarter and Year Ended on 31st March 2026.
5 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Desk No. 491 A, Office No. 4 D Fourth Floor Vardan Tower, Lakhudi Circle Near Sardar Patel Stadium , Navrangpura Ahmedabad Gujarat PIN: 380009 Tel No: NULL Fax No: NULL Email: [email protected] Internet: http://www.johnsonpharmacareltd.live
Registrars
Office No A 106 & 107, Dattani Plaza, East West Compound, Andheri Kurla Road,Safedpul, Sakinaka, Mumbai-400072022-28520461/462 Office No A 106 & 107, Dattani Plaza East West Compound, Andheri Kurla Road Safedpul, Sakinaka PIN: Tel No: 022-28520461/462 Fax No: NULL Email: [email protected]
Management
Ramanlal Trivedi, Whole Time Director & Chief Financial Officer
Manisha Maneklal Patel, Non Executive Independent Director
Parul Agarwal, Non Executive Independent Director
Babita, Non Executive Independent Director
Dheeraj Kumar, Executive Director
Nand Kishore Ray, Non Executive Independent Director
Details
BSE 532154
NSE NULL
ISIN INE560F01022